Show simple item record

dc.contributor.authorKyle J. Dalton
dc.contributor.authorAdewale Troutman
dc.contributor.authorGanna Chornokur
dc.contributor.authorDawood H. Sultan
dc.contributor.authorMeghan E. Borysova
dc.date.accessioned2013-12-13T14:09:57Z
dc.date.accessioned2026-05-19T14:50:26Z
dc.date.available2026-05-19T14:50:26Z
dc.date.issued2013-12-13T14:09:57Z
dc.identifier.urihttp://www.mdpi.com/2076-0760/2/4/247
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/38562
dc.description.abstractProstate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the United States. The American Cancer Society estimates that 238,590 U.S. men will develop PCa and 29,720 men will die from the disease in 2013. PCa exhibits the most profound racial disparities of all cancers with African American men having a 70% higher incidence rate and more than two times higher mortality rate than Caucasian men. Published research on PCa disparities focuses on singular outcomes such as incidence, mortality or quality of life. The objective of this paper is to provide a comprehensive summary of the racial disparities found at each stage of the PCa Care Continuum which includes prevention, detection, treatments, and outcomes and survival. It focuses primarily on disparities among Caucasian (white) and African American men.
dc.publisherMDPI AG
dc.subject.lccSocial Sciences
dc.titleProstate Cancer Disparities throughout the Cancer Control Continuum
dc.typeArticle
dc.description.doi10.3390/socsci2040247
dc.title.journalSocial Sciences
dc.journal.sdgSDG 3
dc.identifier.oaioai:doaj.org/journal:21883d7efa8d423e8cf45309a8998e70


This item appears in the following Collection(s)

Show simple item record